title: Turning biodefense dollars into products.
abstract: Five years after the US anthrax attacks, and more than two years after BioShield legislation was ratified, a survey reveals that biodefense funding has thus far produced only a handful of products for clinical development.
authors.affiliation: BioAbility, LLC, PO Box 14569, Research Triangle Park, North Carolina 27709, USA. mtrull@bioability.com
authors.forename: Melanie C
authors.initials: MC
authors.lastname: Trull
authors.forename: Tracey V
authors.initials: TV
authors.lastname: du Laney
authors.forename: Mark D
authors.initials: MD
authors.lastname: Dibner
mesh_terms: D001709:Biotechnology / Q000191:economics*; D023482:Bioterrorism / Q000191:economics* / Q000517:prevention & control; D002959:Civil Defense / Q000191:economics*; D015510:Clinical Medicine / Q000191:economics*; D004345:Drug Industry / Q000191:economics*; D018581:Technology Transfer; D014481:United States; D014612:Vaccines / Q000191:economics*
chemical_list: D014612:Vaccines